• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by EpiEndo Pharmaceuticals

    News headline image
    EpiEndo Pharmaceutical's ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patients
    From EpiEndo Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Clinical and Pre-Clinical Data on the Novel Barriolide, EP395 (glasmacinal), Published in Three Articles in Pulmonary Pharmacology and Therapeutics
    From EpiEndo Pharmaceuticals
    Via Business Wire
    News headline image
    EpiEndo reports Phase 2A results for lead asset, EP395, in COPD
    From EpiEndo Pharmaceuticals
    Via Business Wire
    News headline image
    EpiEndo commences Phase 2a trial for EP395 in COPD patients
    From EpiEndo Pharmaceuticals
    Via Business Wire
    News headline image
    EpiEndo commences LPS challenge trial for lead candidate EP395
    From EpiEndo Pharmaceuticals
    Via Business Wire
    News headline image
    EpiEndo Pharmaceuticals Expands its Leadership Team, Appointing Stefan Petursson as Chief Financial Officer to Support Future Growth
    From EpiEndo Pharmaceuticals
    Via Business Wire
    News headline image
    EpiEndo Pharmaceuticals wins the Swedish American Life Sciences Summit (SALSS) Rising Star Award 2021
    From EpiEndo Pharmaceuticals
    Via Business Wire
    News headline image
    EpiEndo Pharmaceuticals Secures EUR 20 Million Series A Funding to Advance Clinical Development of its Non-Antibiotic Macrolide for the treatment of COPD
    From EpiEndo Pharmaceuticals
    Via Business Wire
    News headline image
    EpiEndo Pharmaceuticals Announces Launch of First-in-Human Clinical Trial of a Non-Antibiotic Macrolide for the Treatment of Chronic Inflammatory Airway Diseases
    From EpiEndo Pharmaceuticals
    Via Business Wire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.